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Introduction
Diamond-Blackfan anemia (DBA, #MIM105650) is a rare
congenital pure red cell aplasia characterized by nor-
mochromic macrocytic anemia, reticulocytopenia, and nor-
mocellular bone marrow with a selective deficiency of ery-
throid precursors. Forty percent of patients show physical
malformations involving head, thumb, heart and urogenital
system.1,2
Most cases are apparently sporadic, but the disease can be
inherited with an autosomal dominant pattern. Penetrance is
incomplete and expressivity widely variable, even in patients
from the same family.2,3
The major DBA gene, ribosomal protein (RP) S194 is mutat-
ed in approximately 25% of patients.5 Heterozygous muta-
tions in an increasing number of other genes encoding RPs of
the small (RPS7, RPS10, RPS17, RPS24, RPS26) or the large
(RPL5, RPL11, RPL35A) ribosomal subunits have been report-
ed in DBA patients.5-11 However, point mutations in the cod-
ing regions of these genes are present in only 50% of DBA
patients, as shown by a series of sequencing studies that also
included a screening of almost all RP genes.5,8,10
This suggests that DBA has a further genetic heterogeneity
due to non-RP genes or that there are also other mutations
besides those detected by traditional sequencing. Polymerase
chain reaction (PCR)-based methods used for conventional
mutation detection fail to identify heterozygous deletions
because the normal allele masks these mutations. In sequence
analysis, apparent LOH (loss of heterozygosity) of one or
more intragenic single nucleotide polymorphisms (SNPs) may
be the only sign of a deletion in family studies. 
Strategies that detect copy number variations are, there-
fore, necessary to complement sequencing. We previously
used the multiplex ligation-dependent probe amplification
(MLPA) technique to detect RPS19 gene deletions or duplica-
tions.12
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Diamond-Blackfan anemia is an autosomal dominant disease
due to mutations in nine ribosomal protein encoding genes.
Because most mutations are loss of function and detected by
direct sequencing of coding exons, we reasoned that part of
the approximately 50% mutation negative patients may
have carried a copy number variant of ribosomal protein
genes. As a proof of concept, we designed a  multiplex liga-
tion-dependent probe amplification assay targeted to screen
the six genes that are most frequently mutated in Diamond-
Blackfan anemia patients: RPS17, RPS19, RPS26, RPL5,
RPL11, and RPL35A. Using this assay we showed that dele-
tions represent approximately 20% of all mutations. The
combination of sequencing and multiplex ligation-dependent
probe amplification analysis of these six genes allows the
genetic characterization of approximately 65% of patients,
showing that Diamond-Blackfan anemia is indisputably a
ribosomopathy.
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The finding of partial or complete RP deletions/duplica-
tions in DBA patients using CGH array, SNP array or
quantitative PCR has been recently reported.13-15
In order to better characterize the molecular defect in
our cohort of Italian DBA patients who were negative for
RP gene mutations by standard sequencing, we developed
an MLPA synthetic probe set that allows the concurrent
analysis of the six principal RP genes: RPS19, RPL5, RPL11,
RPL35A, RPS17 and RPS26.
Design and Methods
Patients
Patients were selected from the Italian DBA Registry that
includes 173 Italian subjects from 162 families. Diagnosis
was reached following the criteria suggested by the DBA
International Clinical Consensus (ICC) Consortium.2 All the
patients were screened for mutations in ten genes. 
RPS19 mutations were found in 44 of 162 (27%) unre-
lated DBA patients using a strategy that included sequenc-
ing and the MLPA technique. The sequencing analysis of
RPS24, RPS26, RPL5, and RPL11, revealed mutations in 46
of 162 (28%) unrelated patients. No mutations were found
in RPS10, RPS14, RPS16, RPS17, or RPL35A.
Seventy-two (45%) unrelated DBA patients showed no
mutations in these genes and were included in this study.
Informed consent was obtained from all patients and/or
their legal guardians.
MLPA design and method
MLPA oligonucleotide probes were designed according to the
“Designing synthetic MLPA probes” protocol v.8 (MRC-Holland,
Amsterdam, The Netherlands) that uses 12 probes per assay. Each
synthetic probe was composed of two 5′ and 3′ half-probes con-
taining unique target-specific sequence and universal primer
sequences 5′-GGGTTCCCTAAGGGTTGGA and 5′-TCTA-
GATTGGATCTTGCTGGCAC on their 5′ and 3′ ends, respec-
tively. Primers were designed in regions that did not include single
nucleotide polymorphisms (SNPs) (http://genome.ucsc.edu/). 
Because of the constraint of including 12 probes, we were
forced to choose a strategy aimed at the screening of whole gene
deletions or duplications. The probemix contained probes interro-
gating 1-3 exons per each RP gene (Online Supplementary Table S1,
Figure 1A and B). 
MLPA was performed on genomic DNA according to the man-
ufacturer’s instructions. We used the P200-A1 Human DNA refer-
ence kit that includes reference probes and MLPA control frag-
ments (http://www.mrc-holland.com).
The PCR products were diluted 1:15 in water, 1 mL of this solu-
tion was mixed with 10 mL of HiDi formamide (ABI) and 0.2 mL of
ROX500 size standard. The amplification products were separated
by capillary electrophoresis on an ABI 3100 Avant Genetic
Analyzer (Applied Biosystems, Warrington, UK). Genescan v3.7
software was used to analyze the runs and to retrieve peak inten-
sities corresponding to each probe in the different samples and the
integrated peak areas were exported to an Excel 2003 spreadsheet
(Microsoft, CA, USA). 
Normalization was obtained by dividing the peak area of each
probe’s amplification product by the combined peak areas of all
probes (intra-normalization). We then performed an inter-sample
normalization dividing these intra-normalized probe ratios of a
sample by the average intra-normalized probe ratio of all reference
samples (a mixture of DNA samples from healthy individuals).
Threshold values of loss and gain of a genetic material were set
at 0.7 and 1.30, respectively. All samples showing evidence for
deletions or duplications were replicated at least twice.
Characterization of large deletions and duplications
RPS17, RPS19, RPS26, RPL5, RPL11, RPL35A gene copy number
was confirmed by quantitative duplex polymerase chain reaction
(PCR) using primers designed with the Universal Probe Library
(UPL) Technology (http://www.roche-applied-science.com/) (Figure 1A). 
Reactions were carried out in triplicate in a total volume of 20
mL using 10 mL of 2X TaqMan Universal PCR Master mix
(P/N4324018), 1 mL of 20X RNaseP assay as endogenous control
(VIC dye, P/N 4316844), 0.2 mM of forward  and reverse specific
primers, 0.1 mM of specific UPL probe (6FAM, labeled, Roche
Diagnostics) and 20 ng of genomic DNA (Online Supplementary
Table S2).
PCR was performed using thermal cycling conditions suggested
by the manufacturers in a 96-well clear optical reaction plate on an
ABI-Prism7500 Fast instrument (Applied Biosystems).
Gene copy number was calculated using the comparative delta-
delta Ct method: we normalized the DCt of the sample to the DCt
of DNA of a healthy control pool. 
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Table 1. Clinical features of DBA RP deleted/duplicated patients.
Pt (gender) Gene Malformation Response Present Inheritance
status to steroid therapy
treatment
1 (m) RPS17 (del) None NR TD De novo
2 (m) RPS17 (del) Inguinal hernia, NR TD De novo
cryptorchidism
3 (m) RPS17 (del) Short stature NR TD Inherited (mt)
4 (m) RPS17 (del) None NR TD Sporadic
5 (m) RPS19 (del*) None NR TD De novo
6 (m) RPS26 (del) None NR TD De novo
7 (m) RPS26 (del) None NR Death post HSCT De novo
8 (f) RPS26 (del) Cleft palate, NR TD De novo
micrognathia, 
triphlangeal 
thumb, ASD,  
short stature, 
mental retardation
9 (f) RPL5 (del) Flat thenar R SD De novo
eminence, facial 
dysmorphism, mitral
valve insufficiency, 
short stature
10 (m) RPL11 (del) Ambigouous NR TD Inherited (ft)
genitalia, fetal 
hydrops, short 
stature
11 (f) RPL11 (del) Triphlangeal R SD Sporadic
thumb, short 
stature
12 (f) RPL35A (del) None NR Remission De novo
post HSCT
13 (f) RPL35A (del) None R SD De novo
14 (m) RPL35A (del) None na TD Sporadic
15 (f) RPL35A (dup) Short stature R SD Inherited (ft,s)
m: male; f: female; ASD: atrial septal defect; R: responsive to steroid treatment; NR: not responsive
to steroid treatment; na: not administered; SD: steroid-dependent; TD: transfusion-dependent; HSCT:
hematopoietic stem cell transplantation; del: deletion; dup: duplication; del*: partial deletion
(exon 6); mt: mother; ft: father, s: sister. 
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Results and Discussion
MLPA analysis led to the identification of deletions in 14
of 72 patients (19.4%): 4 were in RPS17, 3 in RPS26 and
RPL35A, 2 in RPL11 and one in RPS19 and RPL5. All probes
showed a half-dosage suggesting whole gene deletion in
heterozygosity. Patient 5 showed a partial RPS19 gene
deletion, involving the last exon only (exon 6). All the dele-
tions are expected to suppress the protein expression. In
one patient, a duplication involving the whole RPL35A
gene was identified (Figure 1C). All gene copy number vari-
ations were confirmed by real-time PCR analysis (Figure 2).
Using MLPA, we verified the presence of copy number
changes in the available parents, and  found that in 3 cases
they were inherited: one RPS17 deletion (patient 3), one
RPL11 deletion (patient 10) and the RPL35A duplication
(patient 15). In the remaining cases, deletions are likely to
be de novo or at very low grade of somatic mosaicism
(Table 1). 
All patients with copy number changes (9 males, 6
females) displayed early-onset anemia (age at diagnosis 0-
12 months). All 3 patients with RPL5 or RPL11 deletions,
one patient with RPS17 and one with RPS26 deletion
showed somatic malformations. We did not consider
short stature as a somatic malformation because it was
difficult to evaluate in the context of severe anemia, iron
overload and chronic corticosteroid use. Specifically, the
RPS26 deleted patient had multiple malformations and
Ribosomal protein gene deletions in Diamond-Blackfan anemia
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Figure 1. (A) Schematic drawing showing the loca-
tion of the MLPA (1-3 probes per gene) and real-
time PCR probes (1-4 per gene). NCBI Genomic ref-
erence sequences:  RPS17 NC_000015.9
(82821161..82824865), RPS19 NC_000019.9
(42363988..42375484), RPS26 NC_000012.11
(56435686..56438007), RPL5 NC_000001.10
(93297594..93307481), RPL11 NC_000001.10
(24018269..24022915), RPL35A NC_000003.11
(197677052..197682722).  (B)  MLPA peak corre-
sponding to RP exons. (C) MLPA chromatogram of
patients carrying RP deletion/duplication. Arrows
indicate the MLPA peak corresponding to the delet-
ed/duplicated exon. MLPA peaks: 1=RPL35A exon
1, 2=RPL5 exon 1, 3=RPS19 exon 6, 4=RPS19 exon
2, 5=RPS17 exon 4, 6=RPL5 exon 6, 7=RPS26 exon
4, 8=RPL35A exon 5, 9=RPS26 exon 1, 10=RPL11
exon 4, 11=RPS17 exon 1, 12=RPS19 exon 1. Pt:
patient.
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she was also mentally retarded. As suspected on the basis
of the severe clinical features, this deletion involved also
two genes localized upstream and downstream RPS26
(CDK2 and RNF41 genes) for at least an estimated deletion
extension of ~240 kb. 
A steroid dependence was present in 4 of 15 patients,
and 9 of 15 never responded to steroid treatment and
were, therefore, transfusion dependent. Two patients
underwent hematopoietic stem cell transplantation: one
achieved clinical remission and the other died due to
transplant-related toxicity (Table 1). 
As also shown in our previous work, we support the use
of MLPA as an efficient and rapid assay for the analysis of
gene dosage alterations.12 The main result of this study is
the identification of a relatively high frequency of large
rearrangements in the DBA genes analyzed.
Interestingly, we found for the first time whole-gene
deletions of RPL11 and a complete RPL35A duplication.
Although RP gene deletions are certainly causal, because
all DBA mutations so far are LOF mutations, further stud-
ies are needed to assess whether the RPL35A duplication
is a low-penetrance pathogenetic mutation or a silent vari-
ation (Table 1). 
Mutation screening of the RP genes with a combination
of sequencing and MLPA reached an overall rate of 65%
(105 of 162). In our cohort, genomic deletions in six genes
represent 18% of all mutations. Therefore, deletion
screening should be taken into account in planning diag-
nostic strategies for mutations in DBA genes. Since we
cannot exclude the presence of small exonic deletions or
duplications, our future goal is to produce a multiplex
assay able to screen all exons of the six main genes. In con-
clusion, we developed a reliable and robust MLPA analyt-
ical method for RP DBA genes that represents a useful
complement to DNA sequencing analysis in patients
affected by DBA.
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Figure 2. Real-time PCR results.
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